Overview

Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study

Status:
Unknown status

Trial end date:
2014-06-01

Target enrollment:
0

Participant gender:
All

Summary

Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months. Endpoints: 6 and 12 months of follow-up. Outcome measures: improvement of VA, decrease in central foveal thickness as measured by Optical Coherence Tomography (OCT) and absence of intra/subretinal fluid.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Sao Paulo

Collaborator:

Fundação de Amparo à Pesquisa do Estado de São Paulo

Treatments:

Bevacizumab
Cyclosporine
Cyclosporins

Criteria

Inclusion Criteria:

1. Patients diagnosed with Vogt-Koyanagi-Harada disease based on Revised Diagnostic
Criteria presented by the International Committee on VKH disease in 2001;

2. Presence of choroidal neovascularization identified by fundus biomicroscopy,
fluorescein angiography and OCT.

Exclusion Criteria:

- Media opacities precluding posterior segment exam, ametropia over 5 dioptries,
glaucoma (defined as a disease with characteristic damage at the optic nerve or
characteristic visual field defect with compatible nerve fiber layer lesion), Age
related Macular degeneration, impossibility to increase immunosuppression.